Imagine your vision slowly blurring and your eye swelling after cataract surgery. That's the reality of Irvine-Gass syndrome (IGS), a frustrating complication that can steal a person's clear sight. A new review of past patient records looked at whether injections of a drug called anti-VEGF directly into the eye could help. The review pooled data from 334 patients (343 eyes) who received these injections. After about six months, on average, patients' vision improved and the swelling in the center of their eye decreased. In the few studies that tracked it, the fluid buildup causing the problem resolved in a majority of eyes. This is encouraging news for a condition with limited treatment options. However, it's important to understand what this review can and cannot tell us. The main finding comes with significant caution. The studies were mostly retrospective, meaning researchers looked back at old medical charts rather than designing a controlled experiment. The way different studies reported their main results was too messy to combine for a stronger analysis. Most importantly, we still don't know if these injections work better than a simple placebo injection, because only one small study made that direct comparison. The review suggests potential benefit, but it's a signal calling for better, more definitive research.
Can eye injections help people with Irvine-Gass syndrome see better?
Photo by Dmytro Vynohradov / Unsplash
What this means for you:
Eye injections show promise for Irvine-Gass syndrome, but stronger studies are needed to prove they work best. More on Cystoid Macular Edema
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults.
· Mar 30, 2026
Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
· May 1, 2026
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer
· May 1, 2026
Lower vitreous CREG1 levels associated with reduced ranibizumab response in diabetic macular edema Low CREG1 levels may link to poor treatment response
Frontiers · Apr 30, 2026